The position statements focus on the drugs for treating HIV (Janssen, Gilead, Pharmasyntez), HCV (Janssen, Gilead) and TB (Janssen, Pharmasyntez).

Indian government drug tender process leads to deadly delay in drug supply.

The interim guidance provides advice on the inclusion of bedaquiline in the combination therapy of MDR-TB in accordance with the existing WHO Guidelines for the programmatic management of drug-resistant TB (2011 Update).

The ERS and WHO will now provide scientifically sound and evidence-based advice, and clinical consultation through the Internet to national consiliums and individual practitioners on the management of MDR-TB and other difficult-to-treat TB cases, including TB/HIV and paediatric cases.

Making new TB vaccines available to the world over the next 10-15 years is estimated to cost approximately €600 million, utilizing a highly efficient portfolio approach and adequate funding.

The U.S., India and other nations are facing shortages of tuberculosis drugs - threatening to reverse decades of progress against a deadly disease that is becoming increasingly untreatable.

Based on the survey report findings, the Treatment Action Group and Global TB Community Advisory Board and other civil society members have found that Indian doctors are replacing the banned serological tests with Qiagen’s QuantiFERON-TB Gold.

Now Eastern European and Central Asian Community Advisory Board (EECA CAB), a joint initiative of ITPCru and ECUO, has a website: www.eeca-cab.org/en.

How is it that the wealthiest country on Earth could be forced to resort to a Third World solution to treat a disease as dangerous as TB?

The report of the High-Level Panel of Eminent Persons on the Post-2015 Development Agenda identified tuberculosis investments as highly cost-effective and proposed a specific sub-target on TB as part of a set of goals that could be used to guide development for the 15 years after 2015.